No abstract is provided for this article.
Since progesterone supports endometrial nidation of the fertilized ovum, a progesterone antagonist would theoretically block this process and thus have contraceptive potential. We have explored the ability of RU 486, a newly developed competitive progesterone antagonist, to function as a contraceptive agent. A single oral dose of 10 mg per kilogram of body weight given in the midluteal phase consistently induced menses within 72 hours in women with normal cycles and no risk of pregnancy. Bleeding was not prevented by administration of human chorionic gonadotropin in the midluteal phase. This suggested that giving a single dose of RU 486 late in the menstrual cycle might be an effective contraceptive strategy. This concept was tested in monkeys. When given to rhesus females on day 25 of the cycle, a single intramuscular dose of RU 486 (5 mg per kilogram) prevented pregnancy. The vehicle-treated control animals had a 28 percent pregnancy rate (P less than 0.05 by chi-square analysis). No side effects were noted in women or monkeys. These data suggest that a progesterone antagonist such as RU 486 has the potential to be an effective, safe, and convenient contraceptive agent. Further work will be necessary to assess the safety of long-term monthly administration and to define the optimal dose and time of administration in women.
Multiple sclerosis (MS) is an autoimmune disorder of the central nervous system affecting patients' well-being and quality of life. Pythagorean Self-Awareness Intervention (PSAI) is a novel non-pharmaceutical intervention with significant benefits both in MS and other chronic diseases. In this study, the longstanding effectiveness of PSAI was investigated.This was a two-arm quasi-experimental pragmatic trial in relapsing-remitting MS patients (23 in the PSAI and 21 in the control group). PSAI patients received an 8-week training period and then they performed PSAI at home for another 16 weeks. Assessments took place at baseline, 8 weeks, and 24 weeks. These included cognition, fatigue, perceived stress, and hair cortisol.Significant group × time interactions favoring PSAI were found during the first 8-week period for information processing speed, fatigue, and perceived stress. However, only verbal memory was found to be significantly improved in the PSAI group during the 24-week follow-up period. There were no significant group × time differences with respect to hair cortisol. No side effects were noted and compliance was excellent.PSAI was mostly effective during the first 8-week training period. Its benefits worn out during the non-training period, albeit we observed a delayed significant improvement of verbal memory. Our findings will help to further refine the technique, either by extending the training period and/or by including booster sessions, throughout the PSAI treatment. This study provided Class III evidence for PSAI.
Corticotropin releasing factor (CRF) has recently been identified, purified and shown to be a 41-amino acid polypeptide that stimulates secretion of β-endorphin and ACTH. The metabolic clearance rates (MCR) of I125-CRF and I125-Tyr°CRF were measured in cynomolgus monkeys using the pulse injection and the continuous infusion methods. Hunter-Bolton reagent was used for iodination of CRF and the chloramine-T method for Tyr°-CRF. Gel chromatography was used to separate free iodine (and radioiodinated small fragments) from iodinated CRF in plasma samples. Disappearance of I125-CRF or ll25-Tyr°-CRF could be modeled with two components (bi-exponential). Plasma half-life of I125-CRF was 17.1 + 2.44 min (mean ± SE, n=4) for the fast component and 198 ± 5.3 min for the slow component. The MCR of I125 CRF using the pulse injection technique was 0.44 ± 0.06 L/Kg/d, n=4 and the volume of distribution 213.5 jf 12 ml, n=4, roughly equal to the plasma volume. Continuous infusion of I125-CRF and of I125-Tyr°-CRF gave MCR's ranging between 2.23 − 5.08 L/Kg/d, n=4. I125-ACTH MCR, measured for comparison using the same technique, was 5−10 fold higher. Thus, the plasma half-life of CRF is longer than for all other known hypothalamic peptides and its metabolic clearance rate relatively low and considerably less than that of ACTH. Strong binding of CRF to plasma proteins may be responsible for the small volume of distribution and lower MCR values for the pulse injection method.